Skip to main content
NRIX logo

NRIX · Nurix Therapeutics, Inc.

Track NRIX — free
$12.85 -0.75 (-5.51%)
Market Cap
$1.40B
Shares
109.25M
Volume · Nov 20 2.43M Avg daily vol (3M) 2.46M

Price & Indicators

 

Key stats

Close
$12.85
Fri 20 Nov
Open
$13.40
Fri 20 Nov
Average volume, 30 days
3.6M
shares a session
Short interest
18.9M
17.3% of shares · 7.2 days to cover
Day range
$12.83$13.67
Open $13.40 Close $12.85
52-week closing range
$12.85$27.79
Close $12.85 53.8% under the high
Short volume, last session
32%
Last earnings
Jun 8, 2026
Latest filing
10-Q · Oct 13
Price history
Jul 2020 to Nov 2026

Up next

Jun 7, 2027 Est · unconfirmed · in 28 wks

Latest documents

2026
Nov 18
Investor event
Sanofi ends STAT6 phase one program, partnership continues

Sanofi has terminated the STAT6 phase one program, which it told Nurix about a couple of weeks ago, but the partnership and other STAT6 programs remain in place. Nurix has not yet received any data from Sanofi and has requested full reports.

5 source passages
termination of the stat six phase one program. Which we just found out about from Sanofi, I think a couple weeks ago. They have not terminated the partnership with us, nor the other STAT6 programs that derive from our partnership with them. So far we have not reviewed any of the data. We would like to see the full reports on both the non-clinical tox package and any clinical information they have. Open the document at this passage
Nov 3
Current report 8-K
Sanofi terminates SAR448272 program and milestone eligibility

On November 3, 2026, Nurix Therapeutics, Inc. said Sanofi S.A. will discontinue the Phase 1 first-in-human trial of SAR448272 and terminate the program, eliminating expected future development, regulatory and commercial milestone payments and royalties.

Other events
2 source passages
On November 3, 2026, Nurix Therapeutics, Inc. (the “Company”) announced that collaboration partner Sanofi S.A. (“Sanofi”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi’s decision, the Company does not expect to receive any of the future development, regulatory and commercial milestone payments or royalties for which it was eligible under the Company’s collaboration with Sanofi (the “Sanofi Collaboration”) with respect to the SAR448272 program. Open the document at this passage
Oct 13
Current report 8-K Events of Oct 12
Financial results

Nurix Therapeutics reported revenue of $673.1 million and net income of $549.8 million for the three months ended August 31, 2026, driven primarily by $653.2 million of Roche license revenue, and $1.1 billion in cash, cash equivalents and marketable securities.

Oct 13
Quarterly report 10-Q FY2026 Q3, ended Aug 31
Quarterly report for FY2026 Q3

Nurix Therapeutics posted $373.1 million net income for the nine months ended August 31, 2026, including $653.2 million of Roche license revenue. It held $1.1 billion in cash, cash equivalents and marketable securities and discontinued zelebrudomide in August 2026.

Revenue $673.06M ▲ 8426.3% Net income $549.81M Diluted EPS $4.73
Read from the MD&A section
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$701.94M
Trailing 12 months
Net income (TTM)
$294.88M
Trailing 12 months
Revenue growth YoY
+8,426.3%
Year over year
Operating margin
41.3%
Trailing 12 months
P / E (TTM)
5.9
Trailing earnings · reciprocal yield 16.9%
FCF yield
24.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$720.24M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+38.0%
Year over year · more shares
Price change (1Y)
-5.1%
Trailing year
Short interest
17.3%
Latest settlement · 7.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −36%
below
Price vs 50-day avg −42%
below
RSI (14) 21
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −49%
trailing
6-month return −22%
trailing
YTD return −32%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $22 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +45 funds added
Insider flow Distributing
Net -$707.0K over 90 days · 100% sells
Short interest Falling
17.33% of shares out · ▼ -8.1% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
236 holders — near 3-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Fair
Revenue growth +99%
Y/Y
EPS growth −6%
Y/Y
Free cash flow $-263.5M
Valuation P/E 5.6
below peers
Quant / Vol
risk profile
Very High
Volatility 66%
annualized · 1-yr
Max drawdown −54%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−36% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
21 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $22 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +45 funds added
Insider flow Distributing
Net -$707.0K over 90 days · 100% sells
Short interest Falling
17.33% of shares out · ▼ -8.1% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
236 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $13 · 0% Range high $28
vs 200-day avg -36% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NRIX
Nurix Therapeutics, Inc.
this stock
$1.40B -32.3% +99.3% 5.6 17.3%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
236
% held
109.6%
Net QoQ
+2.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
215
View
Short & Settlement
Short Interest Falling
Shares short
18.9M
Days to cover
7.2d
Change
-1.7M sh
View
Short Volume
Short vol %
32%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
87
Value
$2.1K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
53.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$707.0K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$84.0M
Net income (FY)
$-264.5M
EPS diluted
$-3.05
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
23

Sanofi has terminated the STAT6 phase one program, which it told Nurix about a couple of weeks ago, but the partnership and other STAT6 programs remain in place. Nurix has not yet received any data from Sanofi and has requested full reports.

View
Proposed Sales
Value
$123.1K
Shares
4.8K
Filed
Nov 4, 2026
View
Exempt Offerings
Offering
$120.2M
Filed
Mar 26, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Nurix Therapeutics Appoints Arati…
Published
Nov 11, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
NRIX -17.0% -49.3% -21.5% -52.1% -32.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -8.4% -40.1% -12.3% -43.3% -33.4%
Key facts CIK 1549595 CUSIP 67080M103 13F (30d) 242 filings 224 filers Visit website Investor relations